U.S. Markets open in 8 hrs 1 min

Cardinal Health, Inc. (CAH)

NYSE - NYSE Delayed Price. Currency in USD
70.37+1.36 (+1.97%)
At close: 04:00PM EDT
70.75 +0.38 (+0.54%)
After hours: 07:49PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close69.01
Bid0.00 x 800
Ask0.00 x 800
Day's Range68.53 - 70.50
52 Week Range49.70 - 81.57
Avg. Volume2,581,708
Market Cap18.446B
Beta (5Y Monthly)0.77
PE Ratio (TTM)14.96
Earnings DateN/A
Forward Dividend & Yield1.98 (2.53%)
Ex-Dividend DateDec 30, 2022
1y Target EstN/A
  • PR Newswire

    Swisslog's robotic fulfillment system and software to support new Cardinal Health at-Home Solutions distribution center

    Swisslog, a leading provider of best-in-class warehouse automation and software, has announced that Cardinal Health (NYSE: CAH) will install a Swisslog Automation Solution within its new at-Home Solutions distribution center in Grove City, Ohio. The facility is part of the at-Home Solutions business' multi-year strategy to increase warehouse capacity to accommodate its rapid growth.

  • PR Newswire

    Cardinal Health's Outcomes™ collaborates with Signify Health to offer in-home medication therapy management

    Cardinal Health (NYSE:CAH) today announced its collaboration with Signify Health (NYSE:SGFY) to offer in-home clinical and medication management services through its Outcomes™ business. This collaboration will help reduce costs and eliminate gaps in care for more than 2.3 million members nationwide to support their treatment journey from prescription to pharmacy to home.

  • PR Newswire

    New Cardinal Health report examines shifts in biosimilars industry

    Today, Cardinal Health (NYSE: CAH) released its 2023 Biosimilars Report: Tracking market expansion and sustainability amidst a shifting industry, a publication that highlights provider perceptions, utilization and the latest market trends of biosimilars. The report assesses new and changing perspectives regarding some of the most disruptive biosimilars launched in the areas of immunology and ophthalmology, noting a growing familiarity of the medications among rheumatologists with 76% reporting b